This week's wave of biotech IPO play­ers bumps up of­fer­ings and tar­gets big­ger har­vests of cash

It’s time for the lat­est round of biotech IPO news, which now fo­cus­es on the up­siz­ing process ahead of the pric­ing.

→ For starters, we have In­ozyme Phar­ma, a pre­clin­i­cal start­up out of Boston that is now look­ing to raise $104 mil­lion by sell­ing 6.5 mil­lion shares at $16 a pop. As Re­nais­sance Cap­i­tal notes, they had ini­tial­ly laid out plans to sell 5 mil­lion shares at $14 to $16 each.

→ Next up is South San Fran­cis­co-based An­nex­on, which bumped up its deal size by a hefty 29%. The biotech is now look­ing for around $200 mil­lion by sell­ing 12.5 mil­lion shares at $15 to $16 per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER